ArticleScientific reports2025
Breakthrough hepatitis B virus infection and its associated factors among vaccinated children in Northwest Ethiopia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic characterization of hepatitis B virus from a vaccinated child in Nigeria suggests delayed neonatal immunoprophylaxis rather than vaccine escape: a case report.IJID regions · 2026Article
- Immunological characterization of hepatitis B core antigen antibody among vaccinated adults lacking hepatitis B surface antigen in ethiopia: A multicenter facility-based study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of an effective vaccine, the global prevalence of chronic hepatitis B (CHB) in children was estimated to range from 1.3 to 3.4%. In Ethiopia, the estimated seroprevalence of CHB in children under five years old was 2.21%. This study aimed to assess the prevalence of breakthrough hepatitis B virus (HBV) infection and its associated factors in northwest Ethiopia. A cross-sectional study was conducted in northwest Ethiopia from December 2023 to June 2024. Children aged 1-14 years who visited pediatric clinics for various medical reasons were enrolled. Hepatitis B surface antigen (HBsAg) was tested using an enzyme-linked immunosorbent assay (ELISA). Data were analyzed using SPSS version 23.0. Chi-square tests and logistic regression analyses were employed to identify predictors of breakthrough HBV infection, with statistical significance set at p < 0.05. Among 325 vaccinated children under 15 years of age, the prevalence of breakthrough HBV infection was 2.5% (95% CI: 0.9-4.3%). The age of the children and a history of contact with individuals with CHB were significantly associated with breakthrough infection. Children aged 5-9 years were 10.7 times (OR = 10.7; 95% CI: 1.1-99.6), and those aged 10-14 years were 20.7 times more likely to be infected with HBV (OR = 20.7; 95% CI: 2.0-215.8), compared to children aged 1-4 years. Additionally, children with a history of contact with CHB individuals were six times more likely to be infected with HBV (OR = 6.1; 95% CI: 1.4-27.6). This study found an intermediate prevalence of HBV infection among vaccinated children, which raises significant public health concerns. Age and contact with individuals with CHB were found to be significant factors associated with breakthrough HBV infection. These findings highlight the need for regular evaluation of the effectiveness of vaccination programs and the implementation of targeted preventive strategies to reduce transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.